1. Home
  2. KNSA

as 05-30-2025 4:00pm EST

$
-
-
.
-
-
+
$
-
.
-
-
+
-
.
-
-
%

Stocks

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab.

Founded: 2015 Country:
United Kingdom
United Kingdom
Employees: N/A City: LONDON
Market Cap: 1.9B IPO Year: 2018
Target Price: $38.80 AVG Volume (30 days): 474.9K
Analyst Decision: Strong Buy Number of Analysts: 5
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -0.24 EPS Growth: N/A
52 Week Low/High: $17.38 - $28.56 Next Earning Date: 07-22-2025
Revenue: $481,166,000 Revenue Growth: 59.45%
Revenue Growth (this year): 37.21% Revenue Growth (next year): 5.32%

KNSA Daily Stock ML Predictions

Stock Insider Trading Activity of Kiniksa Pharmaceuticals Ltd. (KNSA)

Name Ticker Relationship Date Transaction AVG Cost Per Share Shares Total Value Securities Owned After Transaction(s) SEC Form 4
Patel Sanj K KNSA CHAIRMAN & CEO May 23 '25 Sell $27.11 86,270 $2,349,981.45 96,674
Patel Sanj K KNSA CHAIRMAN & CEO May 20 '25 Sell $27.02 2,349 $63,469.98 96,674
Tessari Eben KNSA CHIEF OPERATING OFFICER May 19 '25 Sell $26.41 12,000 $316,920.00 72,363
Patel Sanj K KNSA CHAIRMAN & CEO May 13 '25 Sell $27.03 2,872 $77,630.16 96,674
Patel Sanj K KNSA CHAIRMAN & CEO May 7 '25 Sell $27.02 8,095 $218,866.45 96,674
Paolini John F. KNSA CHIEF MEDICAL OFFICER May 7 '25 Sell $27.00 200 $5,400.00 57,403
Megna Michael R KNSA CHIEF ACCOUNTING OFFICER May 7 '25 Sell $26.69 17,647 $470,998.43 32,546
Moat Ross KNSA CHIEF COMMERCIAL OFFICER May 1 '25 Sell $28.00 10,122 $283,416.00 9,415
Ragosa Mark KNSA CHIEF FINANCIAL OFFICER Apr 29 '25 Sell $26.79 88,395 $2,347,335.10 27,009
Moat Ross KNSA CHIEF COMMERCIAL OFFICER Apr 29 '25 Sell $26.62 87,269 $2,265,339.03 9,415

Share on Social Networks: